117 related articles for article (PubMed ID: 37042832)
1. Hypoxia Inhibitor Combined with Chemotherapeutic Agents for Antitumor and Antimetastatic Efficacy against Osteosarcoma.
Zhao TT; Zhou TJ; Zhang C; Liu YX; Wang WJ; Li C; Xing L; Jiang HL
Mol Pharm; 2023 May; 20(5):2612-2623. PubMed ID: 37042832
[TBL] [Abstract][Full Text] [Related]
2. HIF-1α-Mediated Mitophagy Determines ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death both In Vitro and In Vivo.
He G; Pan X; Liu X; Zhu Y; Ma Y; Du C; Liu X; Mao C
ACS Appl Mater Interfaces; 2020 Oct; 12(43):48296-48309. PubMed ID: 33054172
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.
Pourgholami MH; Cai ZY; Badar S; Wangoo K; Poruchynsky MS; Morris DL
BMC Cancer; 2010 Apr; 10():143. PubMed ID: 20398289
[TBL] [Abstract][Full Text] [Related]
4. Nanodelivery of doxorubicin for age-related macular degeneration.
Kelly SJ; Halasz K; Smalling R; Sutariya V
Drug Dev Ind Pharm; 2019 May; 45(5):715-723. PubMed ID: 30704311
[TBL] [Abstract][Full Text] [Related]
5. In situ Co-Delivery of Doxorubicin and Cisplatin by Injectable Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment.
Si M; Xia Y; Cong M; Wang D; Hou Y; Ma H
Int J Nanomedicine; 2022; 17():1309-1322. PubMed ID: 35345787
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-Loaded Microalgal Delivery System for Combined Chemotherapy and Enhanced Photodynamic Therapy of Osteosarcoma.
An X; Zhong D; Wu W; Wang R; Yang L; Jiang Q; Zhou M; Xu X
ACS Appl Mater Interfaces; 2024 Feb; 16(6):6868-6878. PubMed ID: 38294964
[TBL] [Abstract][Full Text] [Related]
7. Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways.
Zeng X; Liu S; Yang H; Jia M; Liu W; Zhu W
J Pharm Pharmacol; 2023 Nov; 75(11):1405-1417. PubMed ID: 37498992
[TBL] [Abstract][Full Text] [Related]
8. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
Qiu R; Sun D; Bai Y; Li J; Wang L
Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
[TBL] [Abstract][Full Text] [Related]
9. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model.
Tan ML; Friedhuber AM; Dass CR
J Pharm Pharmacol; 2013 Jan; 65(1):35-43. PubMed ID: 23215686
[TBL] [Abstract][Full Text] [Related]
10. Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α.
Kim YJ; Lee HJ; Kim TM; Eisinger-Mathason TS; Zhang AY; Schmidt B; Karl DL; Nakazawa MS; Park PJ; Simon MC; Yoon SS
Int J Cancer; 2013 Jan; 132(1):29-41. PubMed ID: 22684860
[TBL] [Abstract][Full Text] [Related]
11. Delivery of MutT homolog 1 inhibitor by functionalized graphene oxide nanoparticles for enhanced chemo-photodynamic therapy triggers cell death in osteosarcoma.
Huang X; Chen J; Wu W; Yang W; Zhong B; Qing X; Shao Z
Acta Biomater; 2020 Jun; 109():229-243. PubMed ID: 32294550
[TBL] [Abstract][Full Text] [Related]
12. CPPs-modified chitosan as permeability-enhancing chemotherapeutic combined with gene therapy nanosystem by thermosensitive hydrogel for the treatment of osteosarcoma.
Cao J; Zhu C; Cao Z; Ke X
Int J Biol Macromol; 2024 May; 267(Pt 2):130915. PubMed ID: 38561118
[TBL] [Abstract][Full Text] [Related]
13. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
[TBL] [Abstract][Full Text] [Related]
14. PEG-conjugated bovine haemoglobin enhances efficiency of chemotherapeutic agent doxorubicin with alleviating DOX-induced splenocardiac toxicity in the breast cancer.
Li B; Zhang J; Ma N; Li W; You G; Chen G; Zhao L; Wang Q; Zhou H
Artif Cells Nanomed Biotechnol; 2023 Dec; 51(1):120-130. PubMed ID: 36905212
[TBL] [Abstract][Full Text] [Related]
15. Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA.
Zhao J; Mu X; Hou X; Zhang X; Li P; Jiang J
Front Oncol; 2023; 13():1111855. PubMed ID: 36756155
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
Li Y; Hou H; Zhang P; Zhang Z
Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
[TBL] [Abstract][Full Text] [Related]
17. Hybrid Cell Membrane-Functionalized Biomimetic Nanoparticles for Targeted Therapy of Osteosarcoma.
Cai JX; Liu JH; Wu JY; Li YJ; Qiu XH; Xu WJ; Xu P; Xiang DX
Int J Nanomedicine; 2022; 17():837-854. PubMed ID: 35228800
[TBL] [Abstract][Full Text] [Related]
18. PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment.
Ma H; He C; Cheng Y; Li D; Gong Y; Liu J; Tian H; Chen X
Biomaterials; 2014 Oct; 35(30):8723-34. PubMed ID: 25017095
[TBL] [Abstract][Full Text] [Related]
19. Light-responsive nanodrugs co-self-assembled from a PEG-Pt(IV) prodrug and doxorubicin for reversing multidrug resistance in the chemotherapy process of hypoxic solid tumors.
Chen T; Xu S; Huang W; Yan D
Biomater Sci; 2022 Jul; 10(14):3901-3910. PubMed ID: 35696997
[TBL] [Abstract][Full Text] [Related]
20. Rational Design of Nanoparticles to Overcome Poor Tumor Penetration and Hypoxia-Induced Chemotherapy Resistance: Combination of Optimizing Size and Self-Inducing High Level of Reactive Oxygen Species.
Deng L; Feng Z; Deng H; Jiang Y; Song K; Shi Y; Liu S; Zhang J; Bai S; Qin Z; Dong A
ACS Appl Mater Interfaces; 2019 Sep; 11(35):31743-31754. PubMed ID: 31389686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
